Loading…
Adrenalectomy in Japanese patients with subclinical Cushing syndrome: 1‐mg dexamethasone suppression test to predict the surgical benefit
Objectives To investigate whether the result of the 1‐mg dexamethasone suppression test can predict the improvement of comorbidities after adrenalectomy in patients with subclinical Cushing syndrome. Methods This retrospective study included 117 subclinical Cushing syndrome patients who underwent ad...
Saved in:
Published in: | International journal of urology 2021-03, Vol.28 (3), p.273-279 |
---|---|
Main Authors: | , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Objectives
To investigate whether the result of the 1‐mg dexamethasone suppression test can predict the improvement of comorbidities after adrenalectomy in patients with subclinical Cushing syndrome.
Methods
This retrospective study included 117 subclinical Cushing syndrome patients who underwent adrenalectomy. The numbers of prescribed drugs for metabolic comorbidities and the clinical variables at diagnosis were compared with those at the follow up. Patients were classified into subgroups according to the result of the 1‐mg dexamethasone suppression test.
Results
Significant improvements in blood pressure, serum cholesterol and body mass index were observed. Furthermore, a significant improvement in glycated hemoglobin was observed in patients with diabetes mellitus. These improvements led to a discontinuation or reduction of prescribed drugs after surgery. In addition, the greatest reduction of prescribed drugs was observed in patients whose serum cortisol levels were between 1.8 and 3.0 µg/dL after the 1‐mg dexamethasone suppression test.
Conclusions
The result of the 1‐mg dexamethasone suppression test can be a useful factor predicting the improvement of comorbidities after adrenalectomy. Current data might give us a new insight into the decision‐making for the treatment of subclinical Cushing syndrome. |
---|---|
ISSN: | 0919-8172 1442-2042 1442-2042 |
DOI: | 10.1111/iju.14445 |